Lupin Limited (BOM:500257)
India · Delayed Price · Currency is INR 2,332.40
+27.95 (1.21%)
At close: Mar 5, 2026
Lupin Revenue
Lupin had revenue of 71.68B INR in the quarter ending December 31, 2025, with 24.27% growth. This brings the company's revenue in the last twelve months to 261.51B, up 18.86% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
261.51B
Revenue Growth
+18.86%
P/S Ratio
4.08
Revenue / Employee
10.89M
Employees
24,006
Market Cap
1.07T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 345.83B |
| Torrent Pharmaceuticals | 127.42B |
| Jubilant Pharmova | 79.18B |
| Abbott India | 68.24B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 38.01B |
| AstraZeneca Pharma India | 21.77B |
Lupin News
- 6 days ago - Lupin Goa facility clears US FDA inspection with VAI classification - Business Upturn
- 9 days ago - Lupin receives USFDA approval for Brivaracetam Oral Solution, launches in US market - Business Upturn
- 17 days ago - Lupin signs licensing and supply agreement with Spektus Pharma to commercialise DeslaFlex in Canada - Business Upturn
- 20 days ago - Lupin Ltd (BOM:500257) Q3 2026 Earnings Call Highlights: Record Growth and Strategic Milestones - GuruFocus
- 20 days ago - Q3 2026 Lupin Ltd Earnings Call Transcript - GuruFocus
- 4 weeks ago - Lupin launches Topiramate Extended-Release Capsules in the US after FDA approval - Business Upturn
- 4 weeks ago - Lupin collaborates with TB Alliance to advance new treatment for Tuberculosis and other mycobacterial diseases - Business Upturn
- 6 weeks ago - Lupin shares in focus today as company sign license and supply agreement for Semaglutide across 23 countries - Business Upturn